Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by high disease burden in some countries, as well as delays in reaching mortality targets due to the long natural history of disease progression to liver cirrhosis and hepatocellular carcinoma.
Infected Blood Inquiry: Second Interim Report
Download
This second interim report from the Infected Blood Inquiry recommends the immediate establishment of a single UK-wide compensation scheme for those infected and affected as part of the infected blood scandal. The scandal saw tens of thousands of people receive contaminated blood through the NHS between the late 1970s and early 1990s, which led to many contracting hepatitis C, hepatitis B, HIV and other diseases. The report recommends the compensation scheme should be run by an arms-length body, chaired by a senior judge and accountable to Parliament, and also calls for the current annual payments under the support schemes to be guaranteed for life.
